92 related articles for article (PubMed ID: 5333877)
1. [On clinical use of high single doses of sarcolysine and exdoxan (cyclophosphan)].
Garin AM; Astrakhan VI; Bychkov MB; Larionov LF; Perevodchikova NI
Vopr Onkol; 1965; 11(10):3-9. PubMed ID: 5333877
[No Abstract] [Full Text] [Related]
2. [Experience in the use of large single doses of sarcolysine in oncological practice].
Garin AM
Vestn Akad Med Nauk SSSR; 1971; 26(3):65-9. PubMed ID: 4931990
[No Abstract] [Full Text] [Related]
3. Multiple myeloma--intermittent combination chemotherapy compared to continuous therapy.
George RP; Poth JL; Gordon D; Schrier SL
Cancer; 1972 Jun; 29(6):1665-70. PubMed ID: 4113171
[No Abstract] [Full Text] [Related]
4. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion.
Storb R; Buckner CD; Dillingham LA; Thomas ED
Cancer Res; 1970 Aug; 30(8):2195-203. PubMed ID: 4990004
[No Abstract] [Full Text] [Related]
5. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
Ringborg U; Lewensohn R
Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
[TBL] [Abstract][Full Text] [Related]
6. [The state of hemopoiesis in the regional perfusion of malignant tumors of the extremities with sarcolysin, thio-TEPA and cyclophosphane].
Levin AO; Babinina VF
Vopr Onkol; 1967; 13(2):48-54. PubMed ID: 4971006
[No Abstract] [Full Text] [Related]
7. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of multiple myeloma with melphalan: 35 personal cases].
Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
[No Abstract] [Full Text] [Related]
9. [Use of large single doses of cyclophosphane (endoxan)].
Garin AM
Vopr Onkol; 1970; 16(11):43-8. PubMed ID: 4929048
[No Abstract] [Full Text] [Related]
10. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
[TBL] [Abstract][Full Text] [Related]
11. [Intermittent melphalan-predniso(lo)ne massive-dose therapy of plasmacytoma].
Braun HJ
Dtsch Med Wochenschr; 1972 Jan; 97(3):84-6. PubMed ID: 5007398
[No Abstract] [Full Text] [Related]
12. Intermittent melphalan therapy in multiple myeloma.
Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
[No Abstract] [Full Text] [Related]
13. Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years.
Kulkarni S; Powles R; Treleaven J; Singhal S; Horton C; Sirohi B; Bhagawati N; Tait D; Saso R; Killick S; Pinkerton R; Atra A; Meller S; Mehta J
Bone Marrow Transplant; 2000 Feb; 25(4):365-70. PubMed ID: 10723578
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenic potency of alkylating agents in rodents and humans.
Dedrick RL; Morrison PF
Cancer Res; 1992 May; 52(9):2464-7. PubMed ID: 1568217
[TBL] [Abstract][Full Text] [Related]
15. [Comparative evaluation of results of treatment of patients with multiple myeloma with fractional doses of sarcolysine and asaline].
Kruglova GV; Merkulova NV; Panicheva EA
Probl Gematol Pereliv Krovi; 1969 Feb; 14(2):21-4. PubMed ID: 5351083
[No Abstract] [Full Text] [Related]
16. The effect of nandrolone phenylpropionate (Durabolin) on the bone-marrow suppression caused by cyclophosphamide.
Cooke WM; Burn JI
Br J Surg; 1971 Apr; 58(4):302-3. PubMed ID: 4929363
[No Abstract] [Full Text] [Related]
17. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of intravenous melphalan in patients with multiple myeloma.
Brox L; Birkett L; Belch A
Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
[No Abstract] [Full Text] [Related]
19. [Toxic hematologic side effects of chemotherapy: nursing interventions].
Schewski R
Pflege Z; 2009 Aug; 62(8):466-9. PubMed ID: 19728437
[No Abstract] [Full Text] [Related]
20. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
